What is the incidence of anaphylaxis during general anesthesia?

Incidence of Anaphylaxis During General Anesthesia

The incidence of anaphylaxis during general anesthesia is approximately 1 in 10,000 to 1 in 20,000 procedures, with significant geographic variation ranging from 1 in 353 to 1 in 18,600 procedures. 1, 2

Key Epidemiologic Data

The most recent and comprehensive data comes from the 2019 international consensus guidelines, which synthesized multiple national databases 1:

• France: Estimated incidence of IgE-mediated reactions of all severity grades is 1 in 10,000, though significant underreporting is suspected
• United Kingdom (NAP6 project): Incidence of severe anaphylaxis (grades III-V) estimated at 1 in 10,000, but likely underestimated—potentially as high as 1 in 7,000 when incomplete data cases are included
• When neuromuscular blocking agents (NMBAs) are administered: The incidence increases to approximately 1 in 6,500 general anesthesias 3, 4

Geographic Variability

The substantial variation in reported incidence (ranging from 1:353 to 1:18,600) reflects multiple factors 1:

• Differences in local drug preferences and practices
• Variability in case ascertainment and referral patterns
• Comprehensiveness of allergy evaluation systems
• Genetic and environmental factors
• Quality of reporting infrastructure

Important caveat: Countries with well-established reporting systems (France, UK, Australia) show higher documented incidence rates, but this likely reflects better detection rather than truly higher occurrence rates. Many countries lack systematic surveillance, making global assessment significantly underestimated 3.

Mortality Data

When anaphylaxis occurs during anesthesia, mortality rates are concerning but relatively consistent across countries 1:

• UK: 1 death per 26.6 cases for all causative drugs
• France: Similar mortality for NMBA-related anaphylaxis
• Western Australia: Mortality rate of 0-1.4% (2000-2009)
• Overall: Approximately 10% of reported reactions to UK regulatory authorities were fatal 2

Primary Causative Agents

The leading causes show geographic variation but consistently include 1:

1. Neuromuscular blocking agents (NMBAs): Major cause in France, Belgium, Australia, and UK
2. Antibiotics: Increasing frequency in most countries, now a leading cause
3. Latex: Decreasing due to prevention measures
4. Chlorhexidine and blue dyes: Increasing due to expanded use

Clinical Recognition

Reassuring finding: Recognition of perioperative anaphylaxis is generally prompt because it occurs in a monitored setting 1. However, one-third of cases in Denmark showed significant delays in epinephrine administration 1, highlighting the need for immediate recognition protocols.

The true incidence remains imperfectly defined due to underreporting of less severe reactions and variable diagnostic criteria across healthcare systems 2. The 60-70% of cases with confirmed IgE-mediated mechanisms suggests that approximately 30-40% represent non-allergic anaphylaxis or other mechanisms 2.